CXCR4 and neoplasm: Furthermore, AMD3100 treatment in an in vivo model of estrogen receptor-positive breast cancer reversed tamoxifen resistance, indicating that the combination of anti-CXCR4 with endocrine therapy could be a more efficient approach for the treatment of this type of tumor [225].